Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952419 · ClinicalTrials.gov registry record · Phase 2
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 474
- Enrollment target
NCT00952419 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 474 participants.
The verdict
NCT00952419, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 474 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after each injection. * To describe the safety of the candidate vaccines after each injection.
Interventions
- BIOLOGICAL Monovalent Subvirion A/H1N1 Influenza vaccine
- BIOLOGICAL Normal saline solution (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00952419
The ClinicalTrials.gov registry entry for NCT00952419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Monovalent Subvirion A/H1N1 Influenza vaccine is the first listed.
NCT00952419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00952419 about?
NCT00952419 is a clinical study titled "A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years". The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after each injection. * To describe the safety of the candidate vaccines after each injection.
What is the current status of trial NCT00952419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 474 participants. The study started on 2009-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00952419?
The interventions under investigation include: Monovalent Subvirion A/H1N1 Influenza vaccine (BIOLOGICAL), Normal saline solution (placebo) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00952419?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.